Table 2 Main patient's characteristics according to HBV treatment history
Never treated | Past treatment | Currently treated | p | |
|---|---|---|---|---|
(n?=?40, 17.9%) | (n?=?66, 29.6%) | (n?=?117, 52.5%) | ||
Demographics | ||||
Sex ratio M/F | 26/13 | 54/11 | 98/17 | 0.03 |
Age m ± sd | 38.7 ± 9.3 | 40.6 ± 10.0 | 43.8 ± 8.0 | 0.007 |
Country of origine | ||||
Europe | 13 (40.6) | 38 (65.5) | 57 (60.6) | 0.007 |
North Africa | 1 (3.1) | 2 (3.4) | 14 (14.9) | |
Sub-Saharan Africa | 14 (43.8) | 17 (29.3) | 21 (22.3) | |
Other | 4 (12.5) | 1 (1.7) | 2 (2.1) | |
Source of infection | ||||
MSM | 10 (29.4) | 25 (42.4) | 50 (51.0) | |
IVDU | 2 (5.9) | 10 (16.9) | 10 (10.2) | 0.045 |
Heterosexual | 19 (55.9) | 21 (35.6) | 34 (34.7) | |
Other | 3 (8.8) | 3 (5.1) | 4 (4.1) | |
Current HAART | 1 (2.5) | 37 (56.1) | 112 (95.7) | <0.001 |
Liver disease | ||||
ALT: m ± sd | 56.2 ± 67.3 | 61.7 ± 68.4 | 89.2 ± 191 | 0.15 |
Metavir A >1 (83) | 2 (20.0) | 10 (43.5) | 19 (38.0) | 0.43 |
Metavir F ≥2 (94) | 9 (64.3) | 13 (52.0) | 21 (38.2) | 0.16 |
Viral and immunological markers | ||||
HBV VL log UI/mL: m ± sd | 5.0 ± 1.7 | 5.6 ± 1.9 | 5.7 ± 1.9 | 0.16 |
HBe Ag + | 22 (59.5) | 19 (32.8) | 25 (25.0) | <0.001 |
HDV+ | 1 (2.5) | 5 (7.9) | 7 (6.1) | 0.72 |
HCV+ | 4 (2.6) | 7 (11.5) | 18 (16.1) | 0.23 |
HIV VL log UI: m ± sd | 4.0 ± 1.4 | 2.9 ± 1.5 | 2.7 ± 1.5 | <0.001 |
CD4 count: m ± sd | 398 ± 223 | 360 ± 266 | 372 ± 301 | 0.41 |
Genotype | ||||
A | 16 (40.0) | 39 (59.1) | 61 (52.1) | 0.02 |
D | 6 (15.0) | 9 (13.6) | 21 (17.9) | |
E | 16 (40.0) | 15 (22.7) | 21 (17.9) | |
G | 0 (0) | 2 (3.0) | 13 (11.1) | |
Other | 2 (4.1) | 1 (2.9) | 1 (0.7) | |
Resistance associated mutations | ||||
Mutation rt173 | 0 | 6 (9.1) | 16 (13.7) | 0.04 |
Mutation rt180 | 1 (2.5) | 22 (33.3) | 41 (35.0) | <0.001 |
Mutation rt181 | 0 | 0 | 5 (4.3) | 0.28 |
Mutation rt204 | 1 (2.5) | 22 (33.3) | 35 (29.9) | <0.001 |